Semaglutide vs AOD-9604

Side-by-side comparison of Semaglutide, AOD-9604 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss
Basics
Molecular type GLP-1 Receptor AgonisthGH C-terminal Fragment
Amino acids 3116
Molecular weight 4,113.6 Da1,815.1 Da
Half-life ~7 days~30 min
Route(s) Subcutaneous injection, Oral (Rybelsus)Subcutaneous, Oral (research)
Mechanism & Research
Primary mechanism Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend… AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri…
Research status FDA Approved Research Compound
Evidence summary Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici… AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si…
Protocol & Dosing
Typical dose 0.25mg → 2.4mg weekly (weight management)300–500 mcg/day
Frequency Once weeklyOnce daily
Duration Ongoing (chronic management)8–12 weeks
Timing Same day each week, any timePre-workout or morning on empty stomach (for metabolic effects)
Safety
Common side effects
  • Nausea (44%)
  • Diarrhoea (30%)
  • Vomiting (24%)
  • Constipation (24%)
  • Injection site redness
  • Mild flushing
  • Headache (transient)
Contraindications
  • Personal/family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia type 2 (MEN2)
  • Pancreatitis history
  • Active cancer (theoretical, given GH receptor homology)
  • Pregnancy (no data)
Anti-doping Not Prohibited Prohibited (WADA S2)
Deeper reading
Related peptides Tirzepatide, AOD-9604, Tesamorelin Semaglutide, Ipamorelin, Tesamorelin
Full profile Read full Semaglutide profile → Read full AOD-9604 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.